153 related articles for article (PubMed ID: 31299584)
1. Design, synthesis, and antifibrosis evaluation of 4-(benzo-[c][1,2,5]thiadiazol-5-yl)-3(5)-(6-methyl- pyridin-2-yl)pyrazole and 3(5)-(6-methylpyridin- 2-yl)-4-(thieno-[3,2,-c]pyridin-2-yl)pyrazole derivatives.
Zhu WJ; Cui BW; Wang HM; Nan JX; Piao HR; Lian LH; Jin CH
Eur J Med Chem; 2019 Oct; 180():15-27. PubMed ID: 31299584
[TBL] [Abstract][Full Text] [Related]
2. 4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5(3)-(6-methylpyridin-2-yl)imidazole and -pyrazole derivatives as potent and selective inhibitors of transforming growth factor-β type I receptor kinase.
Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Park HJ; Park SJ; Sheen YY; Kim DK
Bioorg Med Chem; 2014 May; 22(9):2724-32. PubMed ID: 24704197
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of novel benzo[c][1,2,5]thiadiazol-5-yl and thieno[3,2-c]- pyridin-2-yl imidazole derivatives as ALK5 inhibitors.
Guo Z; Song X; Zhao LM; Piao MG; Quan J; Piao HR; Jin CH
Bioorg Med Chem Lett; 2019 Aug; 29(16):2070-2075. PubMed ID: 31303386
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of the epithelial-to- mesenchymal inhibitory activity of indazole-derived imidazoles as dual ALK5/p38α MAP inhibitors.
Liu YY; Guo Z; Wang JY; Wang HM; Da Qi J; Ma J; Piao HR; Jin CH; Jin X
Eur J Med Chem; 2021 Apr; 216():113311. PubMed ID: 33677350
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Evaluation of 3-Substituted-4-(quinoxalin-6-yl) Pyrazoles as TGF-β Type I Receptor Kinase Inhibitors.
Zhao LM; Guo Z; Xue YJ; Min JZ; Zhu WJ; Li XY; Piao HR; Jin CH
Molecules; 2018 Dec; 23(12):. PubMed ID: 30572609
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of 1-substituted-3-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Mohan AV; Park CY; Son JY; Sheen YY; Kim DK
Bioorg Med Chem Lett; 2011 Oct; 21(20):6049-53. PubMed ID: 21911290
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of 4-(pyridine-4-oxy)-3-(tetrahydro-2H-pyran-4-yl)-pyrazole derivatives as novel, potent of ALK5 receptor inhibitors.
Wang Z; Zhang Y; Wang H; Wang X; Yu Z; Zhao L
Bioorg Med Chem Lett; 2022 Apr; 61():128552. PubMed ID: 35051574
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinolin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
Jin CH; Krishnaiah M; Sreenu D; Rao KS; Subrahmanyam VB; Park CY; Son JY; Sheen YY; Kim DK
Bioorg Med Chem; 2011 Apr; 19(8):2633-40. PubMed ID: 21435890
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
Jin CH; Sreenu D; Krishnaiah M; Subrahmanyam VB; Rao KS; Nagendra Mohan AV; Park CY; Son JY; Son DH; Park HJ; Sheen YY; Kim DK
Eur J Med Chem; 2011 Sep; 46(9):3917-25. PubMed ID: 21696866
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of 5-(fluoro-substituted-6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazoles as inhibitors of transforming growth factor-β type I receptor kinase.
Krishnaiah M; Jin CH; Sheen YY; Kim DK
Bioorg Med Chem Lett; 2015 Nov; 25(22):5228-31. PubMed ID: 26483198
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives as novel potent transforming growth factor-β type 1 receptor inhibitors.
Xu G; Zhang Y; Wang H; Guo Z; Wang X; Li X; Chang S; Sun T; Yu Z; Xu T; Zhao L; Wang Y; Yu W
Eur J Med Chem; 2020 Jul; 198():112354. PubMed ID: 32387837
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of amide derivatives containing the imidazole moiety and evaluation of their anti-cardiac fibrosis activity.
Yang YX; Guo J; Liu C; Nan JX; Wu YL; Jin CH
Arch Pharm (Weinheim); 2024 Apr; ():e2400131. PubMed ID: 38678538
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of the HIF-1α inhibitory activity of 3(5)-substituted-4-(quinolin-4-yl)- and 4-(2-phenylpyridin-4-yl)pyrazoles as inhibitors of ALK5.
Li YW; Li XY; Li S; Zhao LM; Ma J; Piao HR; Jiang Z; Jin CH; Jin X
Bioorg Med Chem Lett; 2020 Jan; 30(2):126822. PubMed ID: 31810777
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological activity evaluation of novel 4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl) oxy) pyridine-2-yl) amino derivatives as potent transforming growth factor-β (TGF-β) type I receptor inhibitors.
Tan B; Zhang X; Quan X; Zheng G; Li X; Zhao L; Li W; Li B
Bioorg Med Chem Lett; 2020 Aug; 30(16):127339. PubMed ID: 32631540
[TBL] [Abstract][Full Text] [Related]
15. Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.
Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Lee HJ; Park SJ; Park HJ; Lee K; Sheen YY; Kim DK
J Med Chem; 2014 May; 57(10):4213-38. PubMed ID: 24786585
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of 4(5)-(6-methylpyridin-2-yl)imidazoles and -pyrazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
Kim DK; Lee YI; Lee YW; Dewang PM; Sheen YY; Kim YW; Park HJ; Yoo J; Lee HS; Kim YK
Bioorg Med Chem; 2010 Jun; 18(12):4459-67. PubMed ID: 20472445
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of 2-benzylamino-4(5)-(6-methylpyridin-2-yl)-5(4)-([1,2,4]triazolo[1,5-a]-pyridin-6-yl)thiazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
Krishnaiah M; Jin CH; Sreenu D; Subrahmanyam VB; Rao KS; Son DH; Park HJ; Kim SW; Sheen YY; Kim DK
Eur J Med Chem; 2012 Nov; 57():74-84. PubMed ID: 23047226
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, evaluation and docking of novel pyrazolo pyrimidines as potent p38α MAP kinase inhibitors with improved anti-inflammatory, ulcerogenic and TNF-α inhibitory properties.
Somakala K; Tariq S; Amir M
Bioorg Chem; 2019 Jun; 87():550-559. PubMed ID: 30928877
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and evaluation of a pyrazolo[3,4-d]pyrimidine derivative as a novel and potent TGFβ1R1 inhibitor.
Wang Y; Liu Y; Zhang Y; Zhang Z; Xu L; Wang J; Yang Y; Hu B; Yao Y; Wei M; Wang J; Tang B; Zhang K; Liu S; Yang G
Eur J Med Chem; 2024 May; 271():116395. PubMed ID: 38626523
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.
Gellibert F; de Gouville AC; Woolven J; Mathews N; Nguyen VL; Bertho-Ruault C; Patikis A; Grygielko ET; Laping NJ; Huet S
J Med Chem; 2006 Apr; 49(7):2210-21. PubMed ID: 16570917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
